- Home
- CNTB vs BOLD Comparison
CNTB vs BOLD Comparison
Compare CNTB & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- BOLD
- Stock Information
- Founded
- CNTB 2012
- BOLD 2018
- Country
- CNTB United States
- BOLD United States
- Employees
- CNTB N/A
- BOLD N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- CNTB Health Care
- BOLD
- Exchange
- CNTB Nasdaq
- BOLD Nasdaq
- Market Cap
- CNTB 68.5M
- BOLD 81.0M
- IPO Year
- CNTB 2021
- BOLD 2024
- Fundamental
- Price
- CNTB $1.17
- BOLD $2.95
- Analyst Decision
- CNTB Strong Buy
- BOLD Strong Buy
- Analyst Count
- CNTB 1
- BOLD 3
- Target Price
- CNTB $8.00
- BOLD $23.00
- AVG Volume (30 Days)
- CNTB 24.6K
- BOLD 57.8K
- Earning Date
- CNTB 09-05-2024
- BOLD 11-11-2024
- Dividend Yield
- CNTB N/A
- BOLD N/A
- EPS Growth
- CNTB N/A
- BOLD N/A
- EPS
- CNTB N/A
- BOLD N/A
- Revenue
- CNTB $24,116,000.00
- BOLD N/A
- Revenue This Year
- CNTB N/A
- BOLD N/A
- Revenue Next Year
- CNTB $63.90
- BOLD N/A
- P/E Ratio
- CNTB N/A
- BOLD N/A
- Revenue Growth
- CNTB N/A
- BOLD N/A
- 52 Week Low
- CNTB $0.68
- BOLD $2.82
- 52 Week High
- CNTB $2.84
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- CNTB 44.02
- BOLD N/A
- Support Level
- CNTB $1.18
- BOLD N/A
- Resistance Level
- CNTB $1.26
- BOLD N/A
- Average True Range (ATR)
- CNTB 0.07
- BOLD 0.00
- MACD
- CNTB -0.01
- BOLD 0.00
- Stochastic Oscillator
- CNTB 13.59
- BOLD 0.00
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.